FemTech

As the FemTech industry experiences significant growth in addressing the needs of women’s health, innovations are rapidly emerging to tackle the gender health gap through advanced technologies and interdisciplinary approaches.

This women-centric focus highlights previously unmet needs and supports the drive for tailored healthcare solutions. However, addressing specific conditions such as menstrual health, reproductive technology, and female oncology presents its challenges, making it imperative to develop culturally sensitive, reliable methods for diverse subpopulations of women, ensuring accessibility and efficacy of emerging technologies.

HGF’s accomplished FemTech team are experts in patent drafting, prosecution, appeals, FTO and infringement opinions, and litigation for large corporate firms, SMEs, universities, and overseas associates. Often working with experts in developmental biology, microbiome technologies, and big data technology companies, our attorneys, with backgrounds in Life Sciences, Chemistry, Electronics, Engineering, and Trade Marks, blend specialist knowledge with critical insights into rapidly evolving FemTech solutions.

We are dedicated to empowering women through innovation, ensuring that intellectual property protection generates new revenue streams, creating substantial business value, and attracting investors.

Latest updates

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a …

Read article
HGF

Rebecca Field recognised in WIPR’s Influential Women in IP 2026

HGF Partner Rebecca Field has been recognised in the 2026 edition of WIPR’s Influential Women in IP, a prestigious listing celebrating women whose expertise, leadership and achievements are shaping the …

Read article

How Low Can You Go? T 0137/24, Percentage Sequence Identity Claims and Divergent EPO and USPTO Approaches

Key takeaways Increasing percentage sequence identity thresholds may be selected from a disclosed convergent list without adding matter, provided the amendment does not create a new technical combination; Broader percentage …

Read article
HGF energy and IP

Fuelling IP: Nuclear Fusion Patents – Is 20 Years Enough?

A patent is often described as providing 20 years of exclusivity. For technologies that take many years to develop, test, license and bring to market, the period of commercially meaningful …

Read article

Designing the Exit: IP Strategy for Venture-Backed Biotech

In venture-built biotech, value is not created at the point of exit, but is designed into the asset from the very beginning. The earliest decisions made around a scientific discovery …

Read article

Five Questions VCs Should Ask About IP Before They Invest

Intellectual property diligence too often starts with the wrong question: how many patents does the company have? For venture investors, that is rarely the most revealing answer. The real issue …

Read article

Miniaturisation and Patentability: Why Scaling Down a Product Is Not Enough to Qualify as a Patentable Invention

Miniaturisation has become a defining trend in modern engineering. From consumer electronics to medical devices, companies constantly strive to make products smaller, lighter, and more portable. This evolution is often …

Read article
Event - 22nd September 2026

HGF are sponsors of LSPN Europe 2026

HGF is proud to sponsor LSPN Europe 2026, the premier event for IP professionals in the life sciences sector. Join us on September 22-23 in Basel for two days packed …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our femtech specialists.